Several DOACs (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF.
Primary risk factors include older age, previous leg injury, deep venous thrombosis, and phlebitis.
Nonprescription options that may be beneficial include immediate-release niacin, omega-3 fatty acids, and soluble fiber.
About 25% of adults worldwide have cardiometabolic syndrome, a combination of metabolic dysfunctions that is challenging to treat and burdensome to healthcare systems.
While positive outcomes with drugs and treatments require prompt intervention, ideally at the first sign of distress, about one-third of women do not experience chest pain when having a heart attack.